Central Nervous System Neoplasm
Conditions
Brief summary
This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors. Studying samples of blood in the laboratory from patients receiving trivalent influenza vaccine may help doctors learn more about the effects of trivalent influenza vaccine on cells. It may also help doctors understand how well patients respond to treatment.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the immunogenicity of high-dose influenza vaccination in patients with central nervous system tumors. SECONDARY OBJECTIVES: I. To assess the geometric mean titer (GMT) in patients after administration of high-dose influenza vaccination compared to previously determined geometric mean titer (GMT) among 38 patients receiving the standard yearly influenza vaccination. II. To assess the seroconversion rates (i.e. four-fold rise in titer) compared to previously determined seroconversion following administration of the standard yearly influenza vaccination. III. To assess the seroprotection rates (i.e. post-vaccination titer \>= 1:40) compared to previously determined seroconversion and seroprotection following administration of the standard yearly influenza vaccination. TERTIARY OBJECTIVES: I. To assess the relationship between serologic markers of immune function and response to high-dose vaccination. OUTLINE: Patients receive trivalent influenza vaccine on day 1. After completion of study, patients are followed up at 28 days and/or 3 months.
Interventions
BIOLOGICALtrivalent influenza vaccine
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a clinical diagnosis of a primary central nervous system tumor * Patients must be eligible to receive the influenza vaccine * Patients must be willing to receive the Fluzone® high-dose seasonal influenza vaccine * Patients must be willing and able to sign an Institutional Review Board (IRB)-approved written informed consent document
Exclusion criteria
* Patients unable to receive the high-dose influenza vaccine due to history of allergy to egg proteins, allergy to influenza vaccine component, acute febrile illness at the time of proposed vaccine administration, history of clinically or virologically confirmed influenza infection in the previous 6 months, contraindication to intramuscular injections, Guillain-Barré syndrome, or other contraindication to the vaccine * Patients who have received the 2013-2014 annual influenza vaccine prior to being considered for enrollment on this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of geometric mean titer (GMT) seroconversion, defined as the percentage of patients with at least a four-fold increase in hemagglutinin inhibition (HI) antibodies | Baseline |
| Estimation of GMT seroconversion, defined as the percentage of patients with at least a four-fold increase in HI antibodies | Day 28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion | Up to 3 months | Categorical variables will be analyzed using chi-square or Fisher exact tests when necessary or appropriate. |
| GMT | Up to 3 months | Continuous values will be analyzed using Wilcoxon rank sum tests to compare high dose influenza vaccine to previously reported data on immunogenicity to the standard trivalent inactivated vaccine. |
| Seroprotection rate, defined as the percentage of patients with a serum HI antibody of at least 1:40 | Up to 3 months | Categorical variables will be analyzed using chi-square or Fisher exact tests when necessary or appropriate. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Serologic markers of immune function | Up to 3 months | To assess the relationship between serologic markers of immune function and response to vaccination, student's t-test will be used. |
| Response to vaccination | Up to 3 months | To assess the relationship between serologic markers of immune function and response to vaccination, student's t-test will be used. |
| Clinical factors such as treatment, disease status, and use of glucocorticoids | Up to 3 months | Logistic regression models adjusting for age and gender will be used to assess the relationship between seroconversion and clinical factors. |
Countries
United States
Outcome results
None listed